Differential Expression of MMPs and TIMPs in Moderate and Severe Heart Failure in a Transgenic Model

Journal of Cardiac Failure

Volumn 12, Issue 4, 2006, Pages 314-325

  Mori, Satsuki ^a   Gibson, Gregory ^a   McTiernan, Charles F ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Heart failure; Matrix metalloproteinases; Remodeling; Tissue inhibitors of MMPs

Indexed keywords

GELATINASE B; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DISEASE COURSE; DISEASE SEVERITY; ELECTROCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART DILATATION; HEART FAILURE; HEART FUNCTION TEST; MALE; MOUSE; NONHUMAN; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; TRANSGENIC ANIMAL; WILD TYPE; ZYMOGRAPHY;

ANIMALS; DISEASE MODELS, ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE; GELATINASES; HEART FAILURE, CONGESTIVE; HUMANS; LUNG; MALE; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MICE; MICE, TRANSGENIC; MYOCARDIUM; ORGAN SIZE; PLEURAL EFFUSION; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 33646204917     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2006.01.009     Document Type: Article

References (65)

1. Chapman R.E., and Spinale F.G. Extracellular protease activation and unraveling of the myocardial interstitium: critical steps toward clinical applications. Am J Physiol Heart Circ Physiol 286 (2004) H1-H10
2. Udelson J.E., and Konstam M.A. Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction. J Card Fail 8 6 Suppl (2002) S465-S471
3. Udelson J.E., Patten R.D., and Konstam M.A. New concepts in post-infarction ventricular remodeling. Rev Cardiovasc Med 4 Suppl 3 (2003) S3-S12
4. Armstrong P.W., Moe G.W., Howard R.J., Grima E.A., and Cruz T.F. Structural remodelling in heart failure: gelatinase induction. Can J Cardiol 10 (1994) 214-220
5. Li H., Simon H., Bocan T.M., and Peterson J.T. MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition. Cardiovasc Res 46 (2000) 298-306
6. Brower G.L., and Janicki J.S. Contribution of ventricular remodeling to pathogenesis of heart failure in rats. Am J Physiol Heart Circ Physiol 280 (2001) H674-H683
7. Sakata Y., Yamamoto K., Mano T., Nishikawa N., Yoshida J., Hori M., et al. Activation of matrix metalloproteinases precedes left ventricular remodeling in hypertensive heart failure rats: its inhibition as a primary effect of angiotensin-converting enzyme inhibitor. Circulation 109 (2004) 2143-2149
8. Tyagi S.C., Kumar S., Voelker D.J., Reddy H.K., Janicki J.S., and Curtis J.J. Differential gene expression of extracellular matrix components in dilated cardiomyopathy. J Cell Biochem 63 (1996) 185-198
9. Spinale F.G., Coker M.L., Heung L.J., Bond B.R., Gunasinghe H.R., Etoh T., et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 102 (2000) 1944-1949
10. Mott J.D., and Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 16 (2004) 558-564
11. McCawley L.J., and Matrisian L.M. Matrix metalloproteinases: they're not just for matrix anymore!. Curr Opin Cell Biol 13 (2001) 534-540
12. Weber K.T. Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 13 (1989) 1637-1652
13. Gunja-Smith Z., Morales A.R., Romanelli R., and Woessner Jr. J.F. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links. Am J Pathol 148 (1996) 1639-1648
14. Docherty A.J., Lyons A., Smith B.J., Wright E.M., Stephens P.E., Harris T.J., et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 318 (1985) 66-69
15. Okada Y., Watanabe S., Nakanishi I., Kishi J., Hayakawa T., Watorek W., et al. Inactivation of tissue inhibitor of metalloproteinases by neutrophil elastase and other serine proteinases. FEBS Lett 229 (1988) 157-160
16. Strongin A.Y., Collier I.E., Bannikov U., Marmer B.L., Grant G.A., and Goldberg G.I. Mechanism of cell surface activation of 72-kDa type IV collagenase. J Biol Chem 270 (1995) 5331-5353
17. Hernandez-Barrantes S., Toth M., Bernardo M.M., Yurkova M., Gervasi D.C., Raz Y., et al. Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation. J Biol Chem 275 (2000) 12080-12089
18. Jo Y., Yeon J., Kim H.J., and Lee S.T. Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system. Biochem J 345 (2000) 511-519
19. Li Y.Y., Feldman A.M., Sun Y., and McTiernan C.F. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 98 (1998) 1728-1734
20. Fedak P.W., Altamentova S.M., Weisel R.D., Nili N., Ohno N., Verma S., et al. Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3. Am J Physiol Heart Circ Physiol 284 (2003) H626-H634
21. Fedak P.W., Smookler D.S., Kassiri Z., Ohno N., Leco K.J., Verma S., et al. TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation 110 (2004) 2401-2409
22. Creemers E.E., Davis J.N., Parkhurst A.M., Leenders P., Dowdy K.B., Hapke E., et al. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 284 (2003) H364-H371
23. Matsumura S., Iwanaga S., Mochizuki S., Okamoto H., Ogawa S., and Okada Y. Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest 115 (2005) 599-609
24. Ducharme A., Frantz S., Aikawa M., Rabkin E., Lindsey M., Rohde L.E., et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106 (2000) 55-62
25. Rohde L.E., Ducharme A., Arroyo L.H., Aikawa M., Sukhova G.H., Lopez-Anaya A., et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99 (1999) 3063-3070
26. Spinale F.G., Coker M.L., Krombach S.R., Mukherjee R., Hallak H., Houck W.V., et al. Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res 85 (1999) 364-376
27. Ogata Y., Enghild J.J., and Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 267 (1992) 3581-3584
28. Spinale F.G., Coker M.L., Thomas C.V., Walker J.D., Mukherjee R., and Hebbar L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res 82 (1998) 482-495
29. Nishikawa N., Yamamoto K., Sakata Y., Mano T., Yoshida J., Miwa T., et al. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation. Card Res 57 (2003) 766-774
30. Kubota T., McTiernan C.F., Frye C.S., Slawson S.E., Lemster B.H., Koretsky A.P., et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 81 (1997) 627-635
31. Li Y.Y., Feng Y.Q., Kadokami T., McTiernan C.F., Draviam R., Watkins S.C., et al. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci U S A 97 (2000) 12746-12751
32. Kadokami T., McTiernan C.F., Kubota T., Frye C.S., and Feldman A.M. Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression. J Clin Invest 106 (2000) 589-597
33. Kadokami T., Frye C., Lemster B., Wagner C.L., Feldman A.M., and McTiernan C.F. Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model. Circulation 104 (2001) 1094-1097
34. Kubota T., Bounoutas G.S., Miyagishima M., Kadokami T., Sanders V.J., Bruton C., et al. Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. Circulation 101 (2000) 2518-2525
35. Higuchi Y., McTiernan C.F., Frye C.B., McGowan B.S., Chan T.O., and Feldman A.M. Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-alpha-induced cardiomyopathy. Circulation 109 (2004) 1892-1897
36. Kubota T., Miyagishima M., Frye C.S., Alber S.M., Bounoutas G.S., Kadokami T., et al. Overexpression of tumor necrosis factor- alpha activates both anti- and pro-apoptotic pathways in the myocardium. J Mol Cell Cardiol 33 (2001) 1331-1344
37. Li Y.Y., McTiernan C.F., and Feldman A.M. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. Cardiovasc Res 42 (1999) 162-172
38. Ramani R., Mathier M., Wang P., Gibson G., Togel S., Dawson J., et al. Inhibition of TNF-receptor 1mediated pathways has beneficial effects in a mouse model of post-ischemic remodeling. Am J Physiol 287 (2004) H1369-H1377
39. Frederiks W.M., and Mook O.R. Metabolic mapping of proteinase activity with emphasis on in situ zymography of gelatinases: review and protocols. J Histochem Cytochem 52 (2004) 711-722
40. Ogata Y., Itoh Y., and Nagase H. Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J Biol Chem 270 (1995) 18506-18511
41. Sundstrom J., Evans J.C., Benjamin E.J., Levy D., Larson M.G., Sawyer D.B., et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 109 (2004) 2850-2856
42. Polyakova V., Hein S., Kostin S., Ziegelhoeffer T., and Schaper J. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol 44 (2004) 1609-1618
43. Thomas C.V., Coker M.L., Zellner J.L., Handy J.R., Crumbley III A.J., and Spinale F.G. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 97 (1998) 1708-1715
44. Peterson J.T., Li H., Dillon L., and Bryant J.W. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res 46 (2000) 307-315
45. Heymans S., Lupu F., Terclavers S., Vanwetswinkel B., Herbert J.M., Baker A., et al. Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol 166 (2005) 15-25
46. Tang Z., McGowan B.S., Huber S.A., McTiernan C.F., Addya S., Surrey S., et al. Gene expression profiling during the transition to failure in TNF-alpha over-expressing mice demonstrates the development of autoimmune myocarditis. J Mol Cell Cardiol 36 (2004) 515-530
47. Spinale F.G. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 90 (2002) 520-530
48. Fowlkes J.L., Serra D.M., Rosenberg C.K., and Thrailkill K.M. Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) functions as an IGF-reversible inhibitor of IGFBP-4 proteolysis. J Biol Chem 270 (1995) 27481-27488
49. Sage E.H., Reed M., Funk S.E., Truong T., Steadele M., Puolakkainen P., et al. Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis. J Biol Chem 278 (2003) 37849-37857
50. Nagatomo Y., Carabello B.A., Coker M.L., McDermott P.J., Nemoto S., Hamawaki M., et al. Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control. Am J Physiol Heart Circ Physiol 278 (2000) H151-H161
51. Mizon-Gerard F., de Groote P., Lamblin N., Hermant X., Dallongeville J., Amouyel P., et al. Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction. Eur Heart J 25 (2004) 688-693
52. Fielitz J., Leuschner M., Zurbrugg H.R., Hannack B., Pregla R., Hetzer R., et al. Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis. J Mol Med 82 (2004) 809-820
53. Han Y.P., Nien Y.D., and Garner W.L. Tumor necrosis factor-alpha-induced proteolytic activation of pro-matrix metalloproteinase-9 by human skin is controlled by down-regulating tissue inhibitor of metalloproteinase-1 and mediated by tissue-associated chymotrypsin-like proteinase. J Biol Chem 277 (2002) 27319-27327
54. Tchougounova E., Lundequist A., Fajardo I., Winberg J.O., Abrink M., and Pejler G. A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 280 (2005) 9291-9296
55. Knäuper H., Will C., López-Otín B., Smith S.J., Atkinson H., Stanton R.M., et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem 271 (1996) 17124-17131
56. Visse R., and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92 (2003) 827-839
57. Tam E.M., Morrison C.J., Wu Y.I., Stack M.S., and Overall C.M. Membrane protease proteomics: isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. Proc Nat Acad Sci U S A 101 (2004) 6917-6922
58. Keller N.R., Sierra-Rivera E., Eisenberg E., and Osteen K.G. Progesterone exposure prevents matrix metalloproteinase-3 (MMP-3) stimulation by interleukin-1alpha in human endometrial stromal cells. J Clin Endocrinol Metab 85 (2000) 1611-1619
59. Lapp C.A., Lohse J.E., Lewis J.B., Dickinson D.P., Billman M., Hanes P.J., et al. The effects of progesterone on matrix metalloproteinases in cultured human gingival fibroblasts. J Periodontol 74 (2003) 277-288
60. Brower G.L., Chancey A.L., Thanigaraj S., Matsubara B.B., and Janicki J.S. Cause and effect relationship between myocardial mast cell number and matrix metalloproteinase activity. Am J Physiol - Heart & Circ Physiol 283 (2002) H518-H525
61. Chancey A.L., Gardner J.D., Murray D.B., Brower G.L., and Janicki J.S. Modulation of cardiac mast cell-mediated extracellular matrix degradation by estrogen. Am J Physiol Heart Circ Physiol 289 (2005) H316-H321
62. Douglas P.S., Katz S.E., Weinberg E.O., Chen M.H., Bishop S.P., and Lorell B.H. Hypertrophic remodeling: gender differences in the early response to left ventricular pressure overload. J Am Col Card 32 (1998) 1118-1125
63. Haghighi K., Schmidt A.G., Hoit B.D., Brittsan A.G., Yatani A., Lester J.W., et al. Superinhibition of sarcoplasmic reticulum function by phospholamban induces cardiac contractile failure. J Biol Chem 276 (2001) 24145-24152
64. Levine B., Kalman J., Mayer L., Fillit H.M., and Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323 (1990) 236-241
65. Torre-Amione G., Kapadia S., Benedict C., Oral H., Young J.B., and Mann D.L. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Col Cardiol 27 (1996) 1201-1206